Indications
Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1). For HCV genotype specific activity, see sections 4.4 and 5.1.
Composition
- Active substance
- daclatasvir dihydrochloride
- International name (INN)
- daclatasvir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Daklinza
- Active substance
- daclatasvir dihydrochloride
- ATC code
- J05AP07
- Therapeutic area
- Hepatitis C, Chronic
- Marketing authorisation holder